The American Academy of Pediatrics (AAP) published updated policy statements and technical reports on October 26, 2026, for influenza prevention and control in children for the 2026–2027 season, along with updated recommendations for respiratory syncytial virus (RSV) disease prevention in infants and children.
Background
Influenza and RSV are leading causes of hospitalization and severe respiratory illness in young children. The AAP has long recommended annual flu vaccination starting at 6 months of age and, more recently, RSV immunization for infants. Previous seasons saw significant pediatric burden, with delayed reports of flu-related deaths continuing to rise. RSV has historically been the top cause of hospitalization in young children, but new monoclonal antibody products have begun to show real-world impact.
What Changed
For influenza:
- The AAP continues to recommend annual influenza vaccination for all children 6 months and older without medical contraindications.
- All U.S. flu vaccines for 2026–2027 are trivalent. The AAP does not prefer one age-appropriate product over another.
- Updated guidance includes more detailed recommendations for immunocompromised children.
- Injectable vaccines now note an increased risk of febrile seizures in children under 5 based on postmarketing data from recent seasons.
- Antiviral treatment (such as oseltamivir) is recommended as early as possible for hospitalized children, those with severe or progressive disease, and children under 5 or in other high-risk groups. Treatment can shorten illness and reduce complications.
For RSV:
- The AAP still recommends RSV immunization (nirsevimab or clesrovimab) for all infants under 8 months born during or entering their first RSV season, unless protected by maternal vaccination during pregnancy (per ACOG guidance).
- For the second season (children 8–19 months), the high-risk criteria have been expanded. Newly included groups: children born preterm at less than 32 weeks’ gestation (regardless of support needs), children with hemodynamically significant congenital heart disease, children with anatomic pulmonary abnormalities or neuromuscular disorders, and children with Down syndrome or other chromosomal differences.
These updates build on real-world effectiveness data showing substantial reductions in hospitalizations.
Competing Viewpoints
Public health agencies and the AAP emphasize broad vaccination to reduce individual and community risk, citing historical data that most pediatric flu deaths occur in unvaccinated children and the proven impact of RSV products. Some parents and clinicians express concerns about vaccine side effects (including the newly noted febrile seizure risk for certain flu shots), cost, access, or preference for natural immunity, especially amid broader vaccine hesitancy discussions. Availability of products and insurance coverage remain practical barriers in some areas. The AAP notes that commercial insurance and the Vaccines for Children program are expected to cover the vaccines as usual.
What to Watch Next
- Uptake rates for the 2026–2027 flu and RSV seasons, particularly among newly eligible second-season high-risk groups.
- Real-world effectiveness data as the seasons progress.
- Any further updates from the AAP, CDC, or ACOG on coadministration or specific populations.
- Pediatric hospitalization trends for flu and RSV this winter.
Parents should talk with their child’s pediatrician about timing, which products are appropriate, and any individual risk factors. These tools are preventive, not perfect, but they have reduced severe outcomes in recent seasons.
Sources: AAP Pediatrics policy statements and technical reports (doi.org/10.1542/peds.2026-078778, 10.1542/peds.2026-079047 and companions), Contemporary Pediatrics summaries, AAP News.
Educational only — not medical advice. Consult your healthcare provider.
Comments (0)
No comments yet.
Sign in to comment.